Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Nephroprotection in Alport Syndrome
NCT00309257Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jan 2004
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benazepril, valsartan and fluvastatin in Alport syndrome, sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Urinary protein excretion. Started Jan 2004; status: completed.
02
Drugs
benazeprilvalsartanfluvastatin
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT00309257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309257.